Amrita Sule
Overview
Explore the profile of Amrita Sule including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
220
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coorens T, Guillaumet-Adkins A, Kovner R, Linn R, Roberts V, Sule A, et al.
Nature
. 2025 Jan;
637(8046):557-564.
PMID: 39815096
Many human diseases are the result of early developmental defects. As most paediatric diseases and disorders are rare, children are critically underrepresented in research. Functional genomics studies primarily rely on...
2.
Sule A, Golding S, Ahmad S, Watson J, Ahmed M, Kellogg G, et al.
Cell Mol Life Sci
. 2022 Nov;
79(12):603.
PMID: 36434396
Ataxia telangiectasia mutated (ATM) is a serine-threonine protein kinase and important regulator of the DNA damage response (DDR). One critical ATM target is the structural subunit A (PR65-S401) of protein...
3.
Ueno D, Vasquez J, Sule A, Liang J, Van Doorn J, Sundaram R, et al.
Oncotarget
. 2022 Sep;
13:1054-1067.
PMID: 36128328
Loss-of-function mutations in genes encoding the Krebs cycle enzymes Fumarate Hydratase () and Succinate Dehydrogenase () induce accumulation of fumarate and succinate, respectively and predispose patients to hereditary cancer syndromes...
4.
Ganesa S, Sule A, Sundaram R, Bindra R
Sci Rep
. 2022 Apr;
12(1):5827.
PMID: 35388070
The methylation status of the O-methylguanine methyltransferase (MGMT) gene promoter has been widely accepted as a prognostic biomarker for treatment with the alkylator, temozolomide (TMZ). In the absence of promoter...
5.
Sule A, Van Doorn J, Sundaram R, Ganesa S, Vasquez J, Bindra R
NAR Cancer
. 2021 May;
3(2):zcab018.
PMID: 34027408
Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations...
6.
Hong C, Vasquez J, Kundishora A, Elsamadicy A, Beckta J, Sule A, et al.
NPJ Genom Med
. 2020 Jun;
5:23.
PMID: 32528726
Similar to their adult counterparts, the prognosis for pediatric patients with high-grade gliomas remains poor. At time of recurrence, treatment options are limited and remain without consensus. This report describes...
7.
Allen J, Wang J, Zolotarskaya O, Sule A, Mohammad S, Arslan S, et al.
J Control Release
. 2020 Feb;
321:36-48.
PMID: 32027939
Glioblastoma multiforme (GBM) is an aggressive and difficult to treat form of brain cancer. In this work, we report on a novel chronotherapeutic polymeric drug, PEAMOtecan, for GBM therapy. PEAMOtecan...
8.
Durant S, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, et al.
Sci Adv
. 2018 Jun;
4(6):eaat1719.
PMID: 29938225
Poor survival rates of patients with tumors arising from or disseminating into the brain are attributed to an inability to excise all tumor tissue (if operable), a lack of blood-brain...
9.
Karlin J, Allen J, Ahmad S, Hughes G, Sheridan V, Odedra R, et al.
Mol Cancer Ther
. 2018 May;
17(8):1637-1647.
PMID: 29769307
Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. A major impediment for clinical implementation is...
10.
Beckta J, Dever S, Gnawali N, Khalil A, Sule A, Golding S, et al.
Oncotarget
. 2017 Jan;
7(36):58716.
PMID: 28039444
No abstract available.